Skip to main content
BIIB
NASDAQ Life Sciences

Biogen Beats Q2 Estimates, Raises Revenue Outlook on Rare-Disease Strength

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$214.745
Mkt Cap
$31.704B
52W Low
$124.556
52W High
$219.72
52W Position info
72% above low
Off High info
2.3% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

BIIB sits 72% above its 52-week low of $124.556.

Summary

Biogen delivered a strong Q2 beat with adjusted EPS of $3.60 vs. $2.95 consensus and revenue of $2.74B vs. $2.46B, driven by rare-disease drugs and the Apellis acquisition. The company raised its full-year revenue guidance to mid-single-digit growth from a prior decline, signaling a turnaround. However, it slashed adjusted EPS guidance to $12-$13 from $14.25-$15.25 due to $3.85/share in acquisition charges. Rare-disease sales grew 11% to $602M, Leqembi rose 15% to $184M, while MS drugs fell 13% to $963M. CEO Viehbacher highlighted the growth portfolio's ability to return Biogen to growth, with late-stage pipeline assets adding upside. Shares rose nearly 5% on the news. This follows the Apellis acquisition close in May and positive Phase 3 lupus data in June, reinforcing the narrative of a pipeline-driven recovery.

At the time of this announcement, BIIB was trading at $214.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.7B. The 52-week trading range was $124.56 to $219.72. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 18, 2026, 11:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $249.28
Real-time Price: $251.18 info
Change: +$1.90 (+0.76%) info
Market Cap: $37.129B info
BIIB
Nov 17, 2026, 4:45 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $253.00
Real-time Price: $251.18 info
Change: -$1.82 (-0.72%) info
Market Cap: $37.129B info
BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $251.18 info
Change: +$2.83 (+1%) info
Market Cap: $37.129B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $251.18 info
Change: -$1.55 (-0.61%) info
Market Cap: $37.129B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $251.18 info
Change: -$1.55 (-0.61%) info
Market Cap: $37.129B info